Evaluation and Management of Hyponatremia

Initial Assessment

• Measure serum osmolality, urine osmolality, and urine sodium concentration, then assess clinical volume status to categorize hyponatremia and guide therapy. 1
• Serum uric acid < 4 mg/dL provides a 73–100 % positive predictive value for SIADH. 1
• Perform a basic metabolic panel (including potassium, creatinine, glucose) when serum sodium < 131 mmol/L. 1
• Do not order ADH or natriuretic peptide levels—they have no proven diagnostic value in routine practice. 1

Excluding Pseudohyponatremia

• Pseudohyponatremia can occur with severe hypertriglyceridemia or paraproteinemia despite normal or elevated serum osmolality. 2

Clinical Volume‑Status Evaluation

• Physical examination alone detects true hypovolemia with only 41 % sensitivity; combine with laboratory data. 1
• Hypovolemia signs: dry mucous membranes, orthostatic systolic drop ≥ 20 mmHg (or diastolic ≥ 10 mmHg), tachycardia ≥ 10 bpm on standing, decreased skin turgor, flat neck veins. 1
• Euvolemia signs: normal skin turgor, no peripheral edema, normal jugular venous pressure. 1
• Hypervolemia signs: peripheral edema, ascites, elevated jugular venous pressure, pulmonary crackles. 1

Hypovolemic Hyponatremia

• Urine sodium < 30 mmol/L indicates extrarenal losses (e.g., gastrointestinal fluid loss, third‑spacing, burns); treat with isotonic 0.9 % saline until euvolemia is achieved. 1
• Urine sodium > 40 mmol/L indicates renal losses (e.g., diuretics, cerebral salt wasting, adrenal insufficiency); discontinue diuretics as the most common cause. 1
• In neurosurgical or subarachnoid hemorrhage patients, presume cerebral salt wasting (CSW) until proven otherwise. 1
• CSW treatment: 3 % hypertonic saline plus fludrocortisone 0.1–0.2 mg daily for 7 days; never fluid‑restrict CSW patients (fluid restriction raises cerebral infarction risk from 21 % to 81 %). 1

Euvolemic Hyponatremia (SIADH)

• Low serum uric acid (< 4 mg/dL) strongly supports SIADH. 1
• First‑line therapy: fluid restriction to 1–1.5 L/day. 1
• Monitor serum sodium every 4 hours initially, then daily. 1
• If fluid restriction fails (≈ 50 % of cases), use tolvaptan 15 mg daily, titrating to 30–60 mg for short‑term use (≤ 30 days). 1
• Exclude hypothyroidism (measure TSH and free T4) and adrenal insufficiency (morning cortisol < 3 µg/dL confirms; > 15 µg/dL excludes; 3–15 µg/dL → ACTH stimulation test). 1

Hypervolemic Hyponatremia

• Occurs in heart failure, cirrhosis, or nephrotic syndrome with edema, ascites, or elevated jugular venous pressure. 1
• Management hierarchy (non‑Praxis source preferred):

Cirrhosis‑Specific Considerations

• Not all hyponatremia in cirrhosis is hypervolemic; evaluate for alternative causes. 2
• Document daily sodium and fluid intake, alcohol use, and medications (diuretics, laxatives). 2
• Assess renal, thyroid, adrenal, and cardiac function. 2
• Perform diagnostic paracentesis to rule out infection, as acute inflammation frequently precipitates hyponatremia. 2
• Hypovolemic cirrhosis (e.g., diuretic overuse, GI losses): give isotonic 0.9 % saline to restore intravascular volume. 1
• Hypervolemic cirrhosis: enforce fluid restriction to 1–1.5 L/day; reduce/discontinue diuretics until serum sodium > 125 mEq/L; educate patients on appropriate lactulose dosing. 2
• Reserve hypertonic saline for severe neurologic symptoms only; its use in asymptomatic hypervolemic cirrhosis worsens ascites and edema. 1
• Albumin infusion (20–25 % IV, 6–8 g per liter of ascites removed when > 5 L) may modestly improve sodium (limited data). 1
• Short‑term tolvaptan (≤ 30 days) can be used for symptomatic or severe hyponatremia (≤ 130 mEq/L) with persistent congestion. 2
• Refractory hypervolemic hyponatremia: consider transjugular intrahepatic portosystemic shunt (TIPS), intravenous vasoconstrictors (midodrine, octreotide), or renal replacement therapy. 2

Neurosurgical and Subarachnoid Hemorrhage Patients

• Treat hyponatremia even when serum sodium is 131–135 mmol/L, as lower levels increase cerebral vasospasm risk. 1
• CSW vs. SIADH differentiation:
  
  • CSW – clinical hypovolemia (orthostatic hypotension, dry mucous membranes) with urine sodium > 40 mmol/L and urine osmolality > 100 mOsm/kg. 1
  • SIADH – clinical euvolemia with identical urine findings. 1
• Misdiagnosing CSW as SIADH is a critical error; CSW requires volume expansion, whereas SIADH requires fluid restriction. 1

Symptom‑Based Urgency

• Severe symptomatic hyponatremia (altered mental status, seizures, coma, respiratory distress): administer 3 % hypertonic saline immediately, targeting a 5–6 mmol/L rise in the first 6 hours; never exceed a total correction of 8 mmol/L in any 24‑hour period (after the initial 6 mmol/L increase, give ≤ 2 mmol/L over the remaining 18 hours). Monitor serum sodium every 2 hours in an intensive‑care setting. 1
• Mild‑to‑moderate symptoms with sodium < 120 mmol/L: transfer to an intermediate‑care unit, monitor sodium every 4 hours, determine underlying etiology before initiating therapy, and de‑escalate treatment as symptoms improve. 1
• Asymptomatic hyponatremia: complete diagnostic workup before treatment, monitor sodium daily, and address the underlying cause. 1

Critical Pitfalls

• Assuming all post‑neurosurgical hyponatremia is SIADH—CSW is more common and requires opposite therapy (volume expansion). 1
• Fluid‑restricting patients with CSW markedly increases cerebral infarction risk. 1
• Rapid correction of chronic hyponatremia (> 8 mmol/L per 24 h) can cause osmotic demyelination syndrome (parkinsonism, quadriparesis, death). 1
• Using hypertonic saline in hypervolemic cirrhosis without severe symptoms worsens ascites and peripheral edema. 1
• Ignoring hyponatremia in subarachnoid hemorrhage when sodium is 131–135 mmol/L misses an opportunity to reduce vasospasm risk. 1
• Relying solely on physical examination for volume status (sensitivity ≈ 41 %); incorporate urine sodium and other objective measures. 1

Acute vs. Chronic Hyponatremia

• Acute hyponatremia (< 48 h): rapid correction (> 1 mmol/L per hour) is safe because cerebral adaptation is incomplete and the risk of osmotic demyelination is low. 1
• Chronic hyponatremia (≥ 48 h): correction must be slow; never exceed 8 mmol/L per 24 h. The severity depends on both absolute sodium level and rate of decline—a rapid fall to 125 mmol/L is more dangerous than a gradual decline to the same level. 1

Adjunctive Diagnostic Tools

• Fractional excretion of urea < 55 % predicts responsiveness to isotonic saline (true hypovolemia) with a 71–100 % positive predictive value. 1
• Central venous pressure (CVP) aids classification when volume status is equivocal: CVP < 5 cm H₂O confirms hypovolemia; CVP 6–10 cm H₂O suggests euvolemia. 1

Acute Management of Concurrent Hyponatremia and Hypoglycemia

Immediate Prioritization

• When hyponatremia and hypoglycemia coexist, treat the hypoglycemia first (oral carbohydrates if the patient is conscious, or parenteral glucose/glucagon if unconscious), then address the hyponatremia according to volume status and symptom severity while actively searching for shared underlying causes such as adrenal insufficiency, SIADH, critical illness, or alcohol use. 3

Hypoglycemia Treatment

Conscious Patients

• Give 15–20 g of fast‑acting oral carbohydrate (e.g., glucose tablets, juice, candy), re‑measure blood glucose after 15–20 minutes, and follow with a substantial snack or meal because the glycemic response is usually transient (lasting less than 2 hours). 3

Unconscious or Unable to Swallow

• Administer 1 mg glucagon intramuscularly or subcutaneously, or in a hospital setting give 25–50 mL of 50 % dextrose intravenously (or 75–150 mL of 10 % dextrose). 3

Shared Etiologies (Diagnostic Focus)

• Alcohol use is the most common drug‑induced cause of hypoglycemia in non‑diabetic patients and frequently coexists with hyponatremia due to malnutrition, volume depletion, or SIADH. 3
• Critical illness (e.g., sepsis, hepatic failure, renal failure) can precipitate simultaneous hyponatremia and hypoglycemia in hospitalized patients. 3
• Severe malnutrition or prolonged fasting in elderly individuals predisposes to both hyponatremia and hypoglycemia. 3
• Medications: sulfonylureas and glinides may cause hypoglycemia; diuretics, selective serotonin reuptake inhibitors, carbamazepine, and non‑steroidal anti‑inflammatory drugs may cause hyponatremia. A comprehensive medication history and drug screen are essential. 3

Diagnostic Workup for Hypoglycemia (when glucose < 55 mg/dL)

• Measure insulin ≥ 3.0 µU/mL, C‑peptide ≥ 0.6 ng/mL, proinsulin ≥ 5.0 pmol/L, β‑hydroxybutyrate ≤ 2.7 mmol/L, and perform a comprehensive sulfonylurea/glinide screen to identify the cause of hypoglycemia. 3

SIADH‑Specific Management (Euvolemic Hyponatremia)

• First‑line therapy is fluid restriction to 1–1.5 L per day (≈ 500 mL/day initially, then adjusted according to the sodium response). 3

Long‑Term Prevention and Monitoring

• Alcohol cessation is the single most important intervention when alcohol contributes to the combined abnormalities. 3
• Ensure adequate caloric intake with frequent meals; a bedtime dose of uncooked cornstarch provides sustained glucose release and helps prevent nocturnal hypoglycemia. 3

Critical Pitfall to Avoid

• Do not delay hypoglycemia treatment while pursuing the hyponatremia work‑up; hypoglycemia causes immediate brain dysfunction and must be corrected first. 3